ACE and cancer: We found, that users of either ARBs or ACE inhibitors separately had lower cancer-specific death risk (HR 0.84, 95% CI: 0.47–1.51 and HR 0.59, 95% CI: 0.38–0.92, respectively) (Supplementary Table 1, Additional file 1).